ArticleThe oncologist2025

First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.

John D Powderly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.